Pharmacometrics is a field of study of the methodology and application of models for disease and pharmacological measurement. It uses mathematical models of biology, pharmacology, disease, and physiology to describe and quantify interactions between xenobiotics and patients (human and non-human), including beneficial effects and adverse effects.[1] It is normally applied to quantify drug, disease and trial information to aid efficient drug development, regulatory decisions and rational drug treatment in patients.

Pharmacometrics uses models based on pharmacology, physiology, and disease for quantitative analysis of interactions between drugs and patients. This involves Systems pharmacology, pharmacokinetics, pharmacodynamics and disease progression with a focus on populations and variability.

Mould and Upton provide an overview of basic concepts in population modeling, simulation, and model-based drug development.[2]

A major focus of pharmacometrics is to understand variability in drug response. Variability may be predictable (e.g. due to differences in body weight or kidney function) or apparently unpredictable (a reflection of the current lack of knowledge).

Origins

The term "pharmacometrics" first appeared in literature in the preface of the 1964 book "Evaluation of Drug Activities: Pharmacometrics"[3]:

The sub-title of the book is, as far as we are aware, a neologism, coined by one of us (A.L.B.), and the word is defined by the main title of the book, which could have been even more explicitly, if more verbosely, expressed as "The Identification and the Comparative Evaluation, Qualitative and Quantitative, of Drug Activities". The term has an etymological precedent in the now widely accepted "Econometrics". We hope it will prove useful for distinguishing the kind of measurement discussed and described in this book from what is nowadays called bioassay; although the same techniques sometimes serve for both, their objectives are not at all identical.

However, the editors later state at the end of the preface:

...we have learned with interest and humility that Dr. Karl Beyer, a Vice-President of Merck, Sharpe and Dohme, Rahway, New Jersey, U.S.A., and current President of the American Pharmacological Society, "coined the word (Pharmacometrics) in the early '50s and has been using it in internal reports ever since" (J. R. Vane, personal communication). Moreover, one of the laboratories in the pharmacological department of his Company is "labeled 'Pharmacometrics'"! We do not know in exactly what sense Dr. Beyer has been using the word, though we find it difficult to think of any other legitimate one than that advanced above. We can only hope that he also thinks so and that its use in the title of this book may help to give it the wider currency that we believe it to deserve and all the "priority" rights to Dr. Beyer.

Types of models

Pharmacokinetics (PK)

Pharmacokinetic models are constructs aimed at characterizing the average pharmacokinetic behavior of a drug within a population. By incorporating inter-individual variability, these models provide insights into central tendencies and variabilities in drug responses across diverse patient groups. Their application extends to the optimization of dosing regimens at a population level.

Pharmacodynamics (PD)

Pharmacodynamic models focus on elucidating the intricate relationship between drug concentration and its effects on the body. This includes both the desired therapeutic effects and potential side effects. By delineating the time course of drug effects, these models contribute to the prediction of efficacy and adverse events, aiding in the identification of optimal dosing strategies.

Physiologically based Pharmacokinetics

Physiologically-Based Pharmacokinetic models integrate physiological information to simulate drug behavior in various tissues and organs. These models consider organ-specific blood flow, tissue permeability, and drug properties, facilitating predictions of drug concentration at specific sites. PBPK models are instrumental in understanding complex drug behaviors.

Exposure-response

Exposure-Response models establish the relationship between drug exposure and clinical response. They play a crucial role in determining the optimal therapeutic range and predicting the likelihood of efficacy or adverse events. These models guide dose individualization based on desired clinical outcomes.

Drug-Drug Interaction

Drug-Drug Interaction models explore the impact of interactions between different drugs on their pharmacokinetics or pharmacodynamics. These models help predict the effects of co-administered drugs on each other, aiding in the identification of potential risks and the adjustment of dosages in the presence of multiple medications.

Disease progression

The natural time course of a disease is often dynamic, with the tendency to become worse without treatment. Disease progression models are mainly used to understand the relationship between treatment, biomarker changes and clinical outcomes. These models describe the disease trajectory, by observing the change in the biomarker level, or the other clinically relevant endpoint that reflects the disease status, over time.[4] There are three key classes of disease progression models: empirical, semi-mechanistic, and systems biology.[5] Most of the disease progression models are empirical, describing disease trajectory rather than the physiological background of the disease.[6] The simplest model that is used to describe disease progression is a linear model when the change of disease status over time is assumed to be constant.

Systems Pharmacology

Systems Pharmacology models integrate pharmacokinetics, pharmacodynamics, and systems biology to provide a comprehensive understanding of drug effects. By considering the intricate interplay between drugs, biological systems, and disease pathways, these models contribute to a holistic approach to drug development and personalized medicine.

Mechanistic Models

Mechanistic models provide a detailed understanding of the underlying biological and physiological processes governing drug behavior. These models offer insights into the mechanisms influencing drug absorption, distribution, metabolism, and elimination, aiding in predicting drug responses in diverse scenarios.

Trial

Trial models describe variations from the nominal trial protocol due to things such as patient dropout and lack of adherence to the dosing regimen.

Organizations

Historically, pharmacometrics has been represented in related clinical pharmacology and statistics organizations. A number of smaller local organizations in Europe, United States, and New Zealand/Australia held local meetings. In the early 1990s, The PAGE meeting was organized and has been held yearly since then, although no official organization was present. Ette and Williams have provided a historical context from which the evolution of pharmacometrics can be appreciated.[7]

In 2011, the American Society of Pharmacometrics (ASoP) was founded by a number of local American groups, and over 600 members worldwide joined ASoP within 6 months. In 2012, ASoP evolved to the International Society of Pharmacometrics (ISoP) to reflect the increasing number of international members. ISoP's growth continues and the Society currently represents over 1000 members from almost 30 countries around the world.[8] Regional groups include PAGE in Europe[9] and PAGANZ in Australia and New Zealand.[10]

Pharmacometricians typically come from disciplines such as Pharmacy, Clinical pharmacology, Statistics, Medicine, or Engineering.

The first professor of pharmacometrics was Mats Karlsson, Uppsala University.[11]

Journals

The main journals that publish work in pharmacometrics are:

  • AAPS J
  • CPT: PSP
  • CPT
  • J PKPD

References

  1. ↑ Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR (May 2008). "Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings". Journal of Clinical Pharmacology. 48 (5): 632–49. doi:10.1177/0091270008315318. PMID 18440922. S2CID 32648945.
  2. ↑ Mould DR, Upton RN (September 2012). "Basic concepts in population modeling, simulation, and model-based drug development". CPT. 1 (9): e6. doi:10.1038/psp.2012.4. PMC 3606044. PMID 23835886.
  3. ↑ Laurence, D.R.; Bacharach, A.L. (1964). Evaluation of Drug Activities: Pharmacometrics. London: Academic Press.
  4. ↑ Ette EI, Williams PJ (2007). Pharmacometrics : the science of quantitative pharmacology. Hoboken, N.J.: John Wiley & Sons. ISBN 978-0-470-08796-1. OCLC 124040246.
  5. ↑ Cook SF, Bies RR (October 2016). "Disease Progression Modeling: Key Concepts and Recent Developments". Current Pharmacology Reports. 2 (5): 221–230. doi:10.1007/s40495-016-0066-x. PMC 5602534. PMID 28936389.
  6. ↑ Schmidt S, Derendorf H (2014). Applied pharmacometrics. New York. ISBN 978-1-4939-1304-6. OCLC 897466424.{{cite book}}: CS1 maint: location missing publisher (link)
  7. ↑ Williams, PJ (2007). Pharmacometrics: The Science of Quantitative Pharmacology. John Wiley & Sons. p. 1.
  8. ↑ International Society of Pharmacometrics (ISoP)
  9. ↑ Population Approach Group Europe (PAGE)
  10. ↑
  11. ↑ "Uppsala Pharmacometrics". Uppsala University.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.